Fitbit Charge 6 Review: ECG Accuracy, Price, and the Edge Successor

Google’s Fitbit Charge 6 (2023) put an FDA cleared ECG and background AFib alerts into a $160 band; now that the Fitbit Edge has replaced it, the question is what a heart screen this cheap can catch.

Between May and October 2020, 455,699 American adults signed up to let their Fitbit devices watch their hearts. LEDs on the underside of each device shone into the skin, an algorithm read the pulse that bounced back, and when the beat stayed ragged long enough, the volunteer was mailed a week-long ECG patch to check the call. When the alert fired again while the patch was on, the patch confirmed atrial fibrillation 98.2 percent of the time.

A later look at the same volunteers found the twist. After a first alert, the researchers estimated, a single 10-second ECG would have confirmed the arrhythmia in only 7.6 percent of people. A four-week monitor would have confirmed it in 60.8 percent. The wrist was rarely wrong. The snapshot was too short.

That tension lives inside the Fitbit Charge 6, the slim tracker Google launched in September 2023 with both an on-demand ECG and those background alerts. As of October 2026 it also has a successor: the $179.99 Fitbit Edge, announced on October 12.

What Is the Fitbit Charge 6, and Has It Been Replaced?

The Fitbit Charge 6 is a fitness tracker made by Fitbit, now part of Google, that pairs continuous optical heart rate, sleep and blood oxygen tracking and built-in GPS with an on-demand electrocardiogram (ECG) app. Google launched it in September 2023 at $160 and replaced it with the Fitbit Edge, announced October 12, 2026.

Google called it its most advanced tracker yet. The headline changes were an improved heart rate sensor and Google services squeezed onto a band: Google Maps, Google Wallet, and YouTube Music controls. It kept two heart features that set Fitbit apart from most bands at the price. The first is the Fitbit ECG App, which the FDA cleared through a 510(k) premarket notification (K200948) in September 2020. The second is Irregular Rhythm Notifications, a background atrial fibrillation (AFib) check built on the optical pulse sensor, which the FDA cleared in April 2022.

Everything else the band reports, from sleep stages to blood oxygen, is a general wellness feature. An FDA clearance covers a specific claim tested in a specific way; it does not turn the rest of the device into a medical instrument.

The bigger change in 2026 happened around the Charge 6 rather than inside it. In May, Google renamed the Fitbit app Google Health, added a Gemini-powered coach, and relaunched Fitbit Premium as Google Health Premium, reported at $9.99 a month at launch. It also launched the Fitbit Air, a screenless band at about $100, and kept moving Fitbit users onto Google accounts. Then came the Fitbit Edge: a $179.99 tracker with a bigger AMOLED screen, built-in GPS, an ECG app, rated battery life of up to seven days, and a battery the owner can replace. It ships October 27, 2026.

The Edge also drops something: it has no NFC chip, so no tap-to-pay. Google’s explanation, as reported at launch, was that fewer than 1 percent of Charge 6 owners paid with their wrist. The Charge 6 is now a previous-generation product. That is a reason to buy it only at the right price, not to dismiss it.

How Does the Fitbit Charge 6 ECG and AFib Detection Work?

The Charge 6 watches your heart in two different ways. LEDs and a light sensor track your pulse continuously, which drives heart rate, sleep data, and the background irregular rhythm check. When you open the ECG app and hold the fingers of your other hand on the band’s electrodes, it records the heart’s electrical signal directly, producing a single-lead tracing that software classifies.

The light on your wrist. Each time the heart’s main pumping chambers contract, they launch a pressure wave through the arteries. When it reaches the tiny vessels under the band, they swell with blood for a fraction of a second, and blood absorbs green light. The sensor sees the skin dim and brighten in rhythm, and the gaps between pulses become a heart rate. The technique is called photoplethysmography, or PPG.

For AFib, the interesting signal is not the rate but the spacing. A healthy heart in sinus rhythm keeps time like a drummer who speeds up and slows down smoothly. In atrial fibrillation, the upper chambers stop contracting in an organized way and quiver instead, bombarding the atrioventricular node, the electrical gatekeeper between upper and lower chambers, with chaotic impulses. Only some get through, at random, so the gaps between beats turn erratic in a pattern cardiologists call “irregularly irregular.” Fitbit’s algorithm hunts for exactly that. In the Fitbit Heart Study version, it analyzed overlapping five-minute windows of pulse intervals and flagged only after 11 consecutive irregular windows, which the investigators describe as at least 30 minutes of irregular rhythm. The design trades speed for certainty. A skipped beat or a few minutes of noisy data will not set it off.

The electrical picture. The ECG app works on a different principle. Every heartbeat starts as an electrical wave that spreads across the upper chambers, pauses at the atrioventricular node, and races through the ventricles. Touching the band with your opposite hand completes a circuit from one arm, across the chest, to the other, and the band records that wave’s voltage. The result is a single view, close to what cardiologists call lead I: a small P wave for the atria, a tall QRS spike for the ventricles, and a T wave as they reset. In AFib, the P wave dissolves into a wavering baseline and the QRS spikes arrive at uneven intervals. The app sorts each recording into sinus rhythm, signs of AFib, or inconclusive.

Think of the two features as a smoke detector and a camera. The PPG alert is the smoke detector: always on, tuned hard against false alarms, unable to show you what is burning. The ECG is the camera: a precise picture, but only of the moment you raise it. A rhythm that comes and goes can be gone by the time you point the camera.

How Accurate Is the Fitbit Charge 6? What the Research Shows

Fitbit’s background AFib alerts are accurate when they fire: in the 455,699-person Fitbit Heart Study, 98.2 percent of repeat alerts matched AFib on an ECG patch. The ECG app is weaker: in an independent Swiss study it caught 66 percent of AFib cases, and about one in five recordings was inconclusive. Heart rate accuracy is a standout.

Heart rate: at the top of its class. The best independent test of the Charge 6 itself comes from KU Leuven in Belgium. In a 2026 JMIR Formative Research study, 45 healthy adults aged 21 to 68 wore ten consumer wearables in climate chambers set to 10, 23, and 36 °C while resting, doing a stress task, walking steadily, and walking in stop-start intervals, with an ECG-based chest strap as the reference. The authors singled out the Charge 6 and the Google Pixel Watch 2 as the most reliable, and the Charge 6 had the better numbers of the two: a mean absolute error of 4.5 beats per minute (5.5 percent) and a concordance of 0.93. The Fitbit Inspire 3, Oura Ring Gen 3, and two Polar watches missed by 9 to 14. Temperature made little difference; stop-start walking raised errors.

The volunteers were healthy. In a small 2025 Digital Health study of 15 cardiac rehabilitation patients in Antwerp, a different Fitbit (the Inspire 2) missed Holter-measured heart rate by an average of 8.3 beats per minute, with the worst accuracy in patients with atrial fibrillation. Irregular rhythms are hard on optical sensors, which is part of why the AFib algorithm waits so long before it speaks.

Background alerts: a giant trial, a precise answer to a narrow question. The Fitbit Heart Study, published in Circulation in 2022, enrolled 455,699 adults without known AFib who already owned compatible Fitbit devices. Their median age was 47; 71 percent were women. Over a median of 122 days, 4,728 participants (1 percent) received an irregular rhythm detection, rising to 4 percent among those 65 and older. Of 1,057 people who were notified and returned an analyzable patch, 340 (32.2 percent) had AFib during the patch week. Among the 225 who had another detection while wearing the patch, 221 were in AFib at that moment: a positive predictive value of 98.2 percent overall and 97.0 percent in people 65 and older.

Those numbers answer a specific question: when the alert fires, is the wearer in AFib right then? They do not answer the one buyers often assume: if it never fires, am I clear? The study was not built to count missed cases. Its volunteers also skewed young and female, an unusual population for a disease that climbs steeply with age. Three of the ten authors worked for Fitbit (Google); the study also had National Institutes of Health support.

A 2025 follow-up of the same cohort, published in Circulation: Arrhythmia and Electrophysiology, explains why a single alert deserves a longer test. Among the 1,057 patch wearers, 57.2 percent had another detection within three months. The investigators then estimated how often different follow-up strategies would confirm AFib after a first alert: 7.6 percent for one 10-second ECG, 19.0 percent for twice-daily 30-second ECGs over a week, 17.4 percent for a 24-hour monitor, 32.2 percent for a one-week monitor, 46.8 percent for two weeks, and 60.8 percent for four weeks. Recurrent alerts were more likely in older people, men, people with vascular disease, and people who slept less. The lesson: an alert is a reason to ask a clinician about extended monitoring, such as the 14-day Zio patch, not a reason to take spot ECGs until one finally catches something.

The ECG app: behind its rivals in independent testing. The best head-to-head data come from the BASEL Wearable Study at University Hospital Basel, published in JACC: Clinical Electrophysiology in 2023. Researchers enrolled 201 consecutive patients at a cardiology service (median age 66.7, 31 percent women), 62 of whom were in AFib, and had each record ECGs on five consumer devices, compared against a 12-lead ECG read by physicians. Fitbit’s ECG, tested on the Fitbit Sense smartwatch, detected AFib with 66 percent sensitivity and 79 percent specificity. The Apple Watch 6 and Samsung Galaxy Watch 3 each reached 85 percent sensitivity and 75 percent specificity; the AliveCor KardiaMobile reached 79 and 69 percent; the Withings ScanWatch, 58 and 75 percent. Fitbit’s algorithm called 21 percent of tracings inconclusive. Yet physicians reading the tracings by hand could determine the rhythm in 99 percent of all recordings. The signal was usually fine; the automated reading was the bottleneck.

Two more Basel analyses sharpen the picture. In a 2023 study in Archives of Cardiovascular Diseases covering 117 patients and 585 tracings, Fitbit’s own algorithm returned a conclusive answer for 81 percent of recordings, while a deep neural network from the French company Cardiologs, whose staff co-authored the paper, did so for 99 percent with similar accuracy. And a 2025 study in JACC: Clinical Electrophysiology of 256 patients and 1,280 single-lead recordings found that 19 percent were labeled inconclusive by at least one device. Pre-existing quirks on a person’s baseline ECG drove much of that: ventricular pacing from a pacemaker raised the odds of an inconclusive result more than sixfold, major signal artifact more than tenfold, and extra beats roughly twofold. If you have a pacemaker, a conduction delay, or frequent premature beats, expect the app to shrug more often.

No peer-reviewed study we found has tested the Charge 6’s ECG specifically; the numbers above come from the Fitbit Sense running the same app. That is a gap, not a verdict.

Even experts find one lead hard. In a 2023 Swiss Medical Weekly survey, 450 clinicians and students interpreted 10,865 single-lead ECGs from five smart devices, including the Fitbit Sense; cardiologists identified AFib with 72 percent sensitivity and 92 percent specificity, and device choice made no significant difference. In the VITAL-AF trial, 15 cardiologists reading handheld single-lead tracings averaged 77.4 percent sensitivity and 73.0 percent specificity (American Heart Journal, 2023). Confirmatory testing matters. For a framework on reading device studies like these, see our guide to what “clinically validated” really means.

What the Fitbit Charge 6 Gets Right

The Charge 6 gets the most important thing right for a budget band: it stacks a passive alert with a strong track record on top of an on-demand ECG, in hardware people will wear day and night, with heart rate accuracy that makes the rest of its data more useful.

Two layers of watching. The alert catches what you would never think to check, and the ECG lets you capture a tracing when you feel a flutter, something a clinician can actually look at.

An alert that is rarely wrong when it speaks. A positive predictive value of 98.2 percent, from a trial of nearly half a million people, is a better pedigree than most consumer health features can claim. If the band says your rhythm looked irregular, call your clinician.

Heart rate you can trust. A mean error of 4.5 beats per minute across rest, stress, and walking matters for everything built on heart rate: training zones, resting trends, and the overnight data behind sleep estimates.

Battery that keeps it on your wrist. A background rhythm check can only work while the device is worn, and adherence is where wearable screening quietly fails. In the Pulsewatch trial of 120 stroke survivors with a mean age of 65, participants wore their smartwatch on average 21.2 of 30 days (JMIR Cardio, 2023). A rated battery life of up to seven days means fewer nights on the charger and more hours of data.

Built-in GPS. Runs, rides, and walks can be mapped without a phone, which makes the band a credible Movement tool rather than a step counter.

Where the Fitbit Charge 6 Falls Short

The Charge 6’s ECG app was less sensitive than Apple and Samsung watches in independent testing and is often inconclusive, its silence proves nothing, and its single lead sees only rhythm. It is also now a previous-generation product in an ecosystem Google has spent 2026 rebuilding.

The ECG misses more than its rivals. In the BASEL Wearable Study, Fitbit’s ECG detected 66 percent of AFib cases, against 85 percent for the Apple Watch 6 and Samsung Galaxy Watch 3, and one in five recordings came back inconclusive. A missed reading during a real episode is exactly the failure that matters.

Silence is not a clean bill of health. The background alert is tuned to avoid false alarms, which means it waits for roughly half an hour of irregular rhythm before it speaks. Short bursts of AFib can slip past it, and no study we found measured how many cases it misses. Anyone with palpitations, breathlessness, or lightheadedness should see a clinician regardless of what the tracker says.

One lead, one rhythm question. A single-lead ECG is built to answer whether the rhythm is sinus or AFib. It cannot detect a heart attack, assess valves or heart muscle, or replace a 12-lead ECG. Chest pain, pressure, or shortness of breath is an emergency: call 911, and do not wait for an app.

Screening the well is still unproven. In 2022 the US Preventive Services Task Force concluded that the evidence was insufficient to weigh the benefits and harms of screening adults 50 and older without symptoms for AFib (JAMA, 2022). Finding AFib earlier is a plausible path to fewer strokes, but that has not been shown in people who feel fine, and anticoagulants carry bleeding risk.

False alarms are not free. In an analysis of the Pulsewatch study, which enrolled people with a history of stroke or transient ischemic attack, receiving false AFib alerts from a smartwatch was associated with a dose-dependent decline in how physically healthy participants felt and in their confidence managing chronic symptoms. Inconclusive ECG results are their own kind of noise. If you are prone to health anxiety, factor that in.

A device at the end of its line. The Charge 6 is a 2023 design, now replaced, running on an app and subscription Google rebuilt in 2026. Buying any device at the end of its product cycle means fewer years of new features ahead.

Fitbit Charge 6 vs Fitbit Edge vs Garmin Venu 3 vs KardiaMobile 6L

The Fitbit Edge is the direct successor, with a bigger screen and replaceable battery but no tap-to-pay. A Garmin Venu 3 doubles the rated battery in a full smartwatch. A KardiaMobile 6L records six-lead ECGs but never watches passively. The Charge 6 is the cheapest way to get both in one band.

Feature	Fitbit Charge 6	Fitbit Edge	Garmin Venu 3	AliveCor KardiaMobile 6L
Form factor	Slim band with screen	Band with larger AMOLED screen	Full smartwatch	Handheld ECG that works with a smartphone
ECG	Single lead, FDA cleared Fitbit ECG App	ECG app included at launch	Single lead, FDA cleared Garmin ECG App, added by update	Six lead, FDA cleared
FDA cleared passive AFib alerts	Yes (Irregular Rhythm Notifications)	Not confirmed in launch coverage	Not confirmed	No; records only when you take a reading
Rated battery	Up to 7 days	Up to 7 days, user-replaceable	Up to 14 days	Not applicable
Status (October 2026)	Replaced by Fitbit Edge; often discounted	Announced October 12, 2026; ships October 27	Superseded by Garmin Venu 4	Standalone ECG device ($150 at launch)

The Edge is the obvious upgrade for a swappable battery and the newest hardware, at about $20 more than the Charge 6’s launch price; if you pay with your wrist, the Charge 6 still does what the Edge cannot. Our Garmin Venu 3 review covers a full smartwatch with Garmin’s FDA cleared ECG app and up to 14 days of rated battery. The AliveCor KardiaMobile 6L captures six views of the heart instead of one. Google’s Fitbit Air is the screenless option, and our Fitbit Sense 2 review covers Fitbit’s older ECG smartwatch. Browse all our cardiology device reviews.

How Much Does the Fitbit Charge 6 Cost, and Is It Covered or HSA/FSA Eligible?

The Charge 6 launched at $160 in September 2023 and has repeatedly dropped to $99.95 at Amazon, its lowest recorded price, including during 2026. As of October 2026, the replacement Fitbit Edge lists at $179.99. Google Health, the app it now runs on, has a free tier and an optional paid Premium tier. We found no evidence that insurers cover it.

Practically, as of October 2026, the price is the whole decision. At $99.95 or close to it, the Charge 6 is a strong value: one of the most reliable heart rate sensors in independent testing, FDA cleared ECG and AFib alerts, built-in GPS, and up to a week of rated battery. At or near its original $160, the case collapses, because about $20 more buys the Edge, with a bigger screen and a replaceable battery.

The ongoing cost depends on whether you want Google’s coaching layer. In 2026 the Fitbit app became Google Health, which has a free basic tier and a paid Google Health Premium tier built around a Gemini-powered coach, reported at $9.99 a month when it launched in May. Because Google relaunched its subscription this year, check inside the Google Health app which heart and sleep features are included free before you pay for anything.

We could not verify that the Charge 6 qualifies for HSA or FSA funds; ask your plan administrator before counting on it.

Who Should Buy the Fitbit Charge 6, and Who Should Skip It?

The Charge 6 suits budget-minded adults who want an accurate everyday tracker with an AFib safety net and an ECG for capturing symptoms, bought at a discount. It is the wrong choice for anyone who needs a diagnosis, has a pacemaker or known conduction disease, or wants the newest hardware.

Good candidates:

• Adults, particularly those over 50, who want a low-cost passive AFib alert on top of normal fitness tracking, and who understand an alert means “see a clinician,” not “you have AFib.”
• People with occasional palpitations who want to capture a tracing in the moment to show their clinician.
• Runners and walkers who want GPS and accurate heart rate without a bulky watch.
• Owners who pay with their wrist and do not want to give that up for the Edge.

Better served by something else:

• Anyone with chest pain, fainting, or a racing heart with shortness of breath: that is an emergency. Call 911.
• People with unexplained symptoms or diagnosed AFib: a clinician-ordered monitor such as the Zio patch records continuously for up to two weeks.
• People with pacemakers, conduction delays, or frequent extra beats, whose recordings are more likely to come back inconclusive on any single-lead device.
• Buyers who can only find it at full price: the Fitbit Edge is the better buy at that point.

If an alert or a symptom sends you looking for a cardiologist or electrophysiologist, the Healthcare Discovery doctor directory lists clinicians by state and specialty.

What This Means for You

Atrial fibrillation is one of the quietest weapons of the Silent Assassin, cardiovascular disease. In the Framingham Study’s 34-year follow-up of 5,070 people, AFib carried a near fivefold excess risk of stroke, and the share of stroke risk attributable to it rose from 1.5 percent in people aged 50 to 59 to 23.5 percent at 80 to 89 (Stroke, 1991). The Task Force noted in 2022 that about one in five people with an AFib-related stroke learn they have AFib only at the time of the stroke or shortly after. That is the gap a wrist alert tries to close, and why AFib belongs in the story we tell in the Four Villains of Health and Longevity.

But a tracker is a measurement, not a medicine. The Charge 6’s best contribution may be the unglamorous one: accurate heart rate and GPS that make Movement measurable, and a battery that lets it stay on overnight so Sleep is tracked rather than guessed. The Fitbit Heart Study’s finding that people who slept less had more recurrent alerts is an association, not proof of cause, but it points in a familiar direction.

Then there is Mindset. A heart screen on your wrist can be quiet reassurance or a steady drip of worry. Use the Charge 6 as designed: let the alert work in silence, take an ECG when you feel something, and treat any flag as the start of a conversation with a clinician, not a verdict. The wrist, as the half-million volunteers of 2020 showed, is rarely wrong when it speaks. It just cannot see everything.

Frequently Asked Questions

Sources

1. Lubitz SA, et al. Detection of atrial fibrillation in a large population using wearable devices: the Fitbit Heart Study. Circulation, 2022. DOI
2. Lubitz SA, et al. Wearable irregular heart rhythm detection recurrences and electrocardiographic atrial fibrillation confirmation: the Fitbit Heart Study. Circulation: Arrhythmia and Electrophysiology, 2025. DOI
3. Gielen J, et al. Accuracy of optical heart rate measurements for 10 commercial wearables in different climate conditions and activities. JMIR Formative Research, 2026. DOI
4. Vermunicht P, et al. Continuous heart rate measurements in patients with cardiac disease: device comparison and development of a novel artefact removal procedure. Digital Health, 2025. DOI
5. Mannhart D, et al. Clinical validation of 5 direct-to-consumer wearable smart devices to detect atrial fibrillation: BASEL Wearable Study. JACC: Clinical Electrophysiology, 2023. DOI
6. Mannhart D, et al. Clinical validation of an artificial intelligence algorithm offering cross-platform detection of atrial fibrillation using smart device electrocardiograms. Archives of Cardiovascular Diseases, 2023. DOI
7. Isenegger C, et al. Inconclusive single-lead ECGs from smart devices: impact of baseline ECG anomalies. JACC: Clinical Electrophysiology, 2025. DOI
8. Weidlich S, et al. Accuracy in detecting atrial fibrillation in single-lead ECGs: an online survey comparing the influence of clinical expertise and smart devices. Swiss Medical Weekly, 2023. DOI
9. Pipilas DC, et al. Accuracy and variability of cardiologist interpretation of single lead electrocardiograms for atrial fibrillation: the VITAL-AF trial. American Heart Journal, 2023. DOI
10. Ding EY, et al. Accuracy, usability, and adherence of smartwatches for atrial fibrillation detection in older adults after stroke (Pulsewatch). JMIR Cardio, 2023. DOI
11. Tran KV, et al. False atrial fibrillation alerts from smartwatches are associated with decreased perceived physical well-being and confidence in chronic symptoms management. Cardiology and Cardiovascular Medicine, 2023. DOI
12. US Preventive Services Task Force. Screening for atrial fibrillation: recommendation statement. JAMA, 2022. DOI
13. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke, 1991. DOI
14. U.S. Food and Drug Administration. 510(k) premarket notification K200948, Fitbit ECG App. FDA database
15. Google. Fitbit gains US and Europe clearance for ECG app to identify AFib (company announcement), September 2020. Google
16. Google. New Fitbit feature makes AFib detection more accessible (Irregular Rhythm Notifications, company announcement), April 2022. Google
17. Google. Introducing Fitbit Charge 6: our most advanced tracker yet (company announcement), September 2023. Google
18. Google. Fitbit Charge 6 technical specifications. Google Store
19. Google. Google Fitbit Edge: our all-new smartest fitness tracker ever (company announcement), October 2026. Google